Sheldon L. Koenig
2023 - Esperion Therapeutics
In 2023, Sheldon L. Koenig earned a total compensation of $3M as President and Chief Executive Officer at Esperion Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $541,938 |
|---|---|
| Option Awards | $1,267,661 |
| Salary | $720,833 |
| Stock Awards | $422,100 |
| Other | $16,033 |
| Total | $2,968,565 |
Koenig received $1.3M in option awards, accounting for 43% of the total pay in 2023.
Koenig also received $541.9K in non-equity incentive plan, $720.8K in salary, $422.1K in stock awards and $16K in other compensation.
Rankings
In 2023, Sheldon L. Koenig's compensation ranked 311th out of 3,006 executives tracked by ExecPay. In other words, Koenig earned more than 89.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 311 out of 3,006 | 90th |
Division Manufacturing | 171 out of 1,650 | 90th |
Major group Chemicals And Allied Products | 115 out of 918 | 88th |
Industry group Drugs | 112 out of 881 | 87th |
Industry Pharmaceutical Preparations | 71 out of 637 | 89th |
Source: SEC filing on April 11, 2024.
Koenig's colleagues
We found two more compensation records of executives who worked with Sheldon L. Koenig at Esperion Therapeutics in 2023.
News
Esperion Therapeutics CEO Sheldon Koenig's 2023 pay falls 22% to $3M
April 11, 2024
Esperion Therapeutics CEO Sheldon Koenig's 2022 pay falls 51% to $3.8M
April 13, 2023
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Portola Pharmaceuticals CEO Scott Garland's 2019 pay falls 24% to $4.4M
April 20, 2020